Zahid H Siddik

List of Publications by Year
in descending order

34 papers	4,257 citations	361413 20 h-index	477307 29 g-index
35 all docs	35 docs citations	35 times ranked	7558 citing authors

#	Article	IF	Citations
1	Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22, 7265-7279.	5.9	2,838
2	Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene, 2005, 24, 2929-2943.	5.9	231
3	Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Analytical Biochemistry, 1987, 163, 21-26.	2.4	137
4	Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clinical Cancer Research, 2009, 15, 3770-3780.	7.0	128
5	Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Seminars in Cancer Biology, 2019, 58, 65-79.	9.6	94
6	Tissue Platinum Concentration and Tumor Response in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3345-3352.	1.6	81
7	Recent Developments in Texaphyrin Chemistry and Drug Discovery. Inorganic Chemistry, 2013, 52, 12184-12192.	4.0	65
8	Elevated Glutathione Levels Confer Cellular Sensitization to Cisplatin Toxicity by Up-Regulation of Copper Transporter hCtr1. Molecular Pharmacology, 2008, 74, 697-704.	2.3	63
9	Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie - International Edition, 2016, 55, 12626-12631.	13.8	61
10	New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status. Oncotarget, 2017, 8, 490-505.	1.8	61
11	Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochemical Pharmacology, 2012, 83, 1049-1062.	4.4	60
12	ATP11B mediates platinum resistance in ovarian cancer. Journal of Clinical Investigation, 2013, 123, 2119-2130.	8.2	56
13	Chemical and Biological Studies on a Series of Novel (trans-(1R,2R)-,trans-(1S,2S)-,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 267 T 1997, 40, 112-116.	6.4	52
14	The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecologic Oncology, 2011, 122, 402-409.	1.4	49
15	Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7021-7029.	7.1	42
16	Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. Journal of Cancer Research and Clinical Oncology, 2003, 129, 709-718.	2.5	29
17	A texaphyrinâ€“oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. MedChemComm, 2012, 3, 1275.	3.4	27
18	Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrinâ€“platinum conjugate. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1701-1705.	2.2	25

#	Article	IF	Citations
19	Synthesis and antitumor activity of 1,2-diaminocyclohexane platinum(IV) complexes. Journal of Inorganic Biochemistry, 1994, 54, 39-47.	3.5	20
20	Photoinduced Reduction of PtIVwithin an Anti-Proliferative PtIV-Texaphyrin Conjugate. Chemistry - A European Journal, 2014, 20, n/a-n/a.	3.3	17
21	Gadolinium texaphyrin (Gd-Tex)-malonato-platinum conjugates: Synthesis and comparison with carboplatin in normal and Pt-resistant cell lines. Dalton Transactions, 2009, , 10834.	3.3	16
22	Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Oncotarget, 2017, 8, 10905-10918.	1.8	15
23	Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie, 2016, 128, 12816-12821.	2.0	13
24	Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation. Molecular Cancer Research, 2017, 15, 328-339.	3.4	12
25	Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog. Prostate, 2005, 62, 91-100.	2.3	10
26	Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemotherapy and Pharmacology, 2010, 65, 427-436.	2.3	10
27	Cisplatin Resistance. , 2006, , 283-307.		7
28	Apoptosis in Cancer. , 2014, , 357-390.		4
29	Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill. Molecular Pharmacology, 2020, 97, 237-249.	2.3	4
30	Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents. Cancer Chemotherapy and Pharmacology, 2020, 85, 1129-1140.	2.3	2
31	Drug Resistance and the Tumor Suppressor p53: The Paradox of Wild-Type Genotype in Chemorefractory Cancers. , 2009, , 209-231.		2
32	Frontispiz: Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie, 2016, 128, .	2.0	0
33	Frontispiece: Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie - International Edition, 2016, 55, .	13.8	0
34	Targeting p21-Dependent Pathways for Cell Death in Cancer Therapy. , 2010, , 199-213.		0